Get the latest Silexion Therapeutics Corp (SLXN) stock news and headlines to help you in your trading and investing decisions.

Company’s New Groundbreaking Preclinical Data in NSCLC Models Provides Further Validation for SIL204's Innovative Delivery ...

Silexion Therapeutics is a pioneering clinical-stage, oncology-focused biotechnology company developing innovative RNA interference (RNAi) therapies to treat solid tumors driven by KRAS mutations ...

Silexion Therapeutics will present its KRAS-targeting RNAi therapy at the 2025 ASCO Gastrointestinal Cancers Symposium in January.

Silexion Therapeutics reports positive preclinical results for SIL204 in lung cancer, advancing dual-route administration and preparing for upcoming clinical trials.

About Silexion Therapeutics Silexion Therapeutics is a pioneering clinical-stage, oncology-focused biotechnology company developing innovative RNA interference (RNAi) therapies to treat solid ...

Silexion Therapeutics (NASDAQ: SLXN) is a pioneering clinical-stage, oncology-focused biotechnology company developing innovative RNA interference (RNAi) therapies to treat solid tumors driven by ...

Cayman Islands, January 15, 2025 – Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for ...

New analysis from Silexion's Phase 2 trial of LODER shows a 56% objective response rate (ORR) and 67% resectability improvement in non-resectable pancreatic cancer ...